David E. Redlick

Retired Partner

David Redlick is a retired partner in the Corporate and Life Sciences Group. His practice focused on corporate and securities law, with an emphasis on public offerings, mergers and acquisitions, venture capital transactions and corporate collaborations. For more than 30 years, Mr. Redlick served as counsel for a broad range of clients, including public and private life sciences and high technology companies, investment banks and venture capital funds. Mr. Redlick has been rated by Chambers USA and Chambers Global in Band 1 in the Life Sciences: Corporate/Commercial category and has been recognized as a "Leading Lawyer" in life sciences by Legal 500 United States. Mr. Redlick was recently included in the Chambers shortlist for selection of the 100 top business lawyers in the United States.

Professional Activities

Mr. Redlick has served as a:

  • member of the Overseers Committee of Brigham and Women’s Hospital;  
  • guest lecturer at Sloan School of Management of The Massachusetts Institute of Technology and Kellogg School of Management at Northwestern University on subject of biotechnology initial public offerings;
  • member of the Executive Committee of the Board of Directors of the Greater Boston Chamber of Commerce;
  • co-chair of Governor William Weld’s Task Force on Marketing Massachusetts;
  • member of the Board of Associates of the Whitehead Institute for Biomedical Research (affiliated with The Massachusetts Institute of Technology); and
  • trustee of the Massachusetts College of Art.


Recent Highlights

Representation of clients in:

Initial Public Offerings

  • Ophthotech (issuer)
  • Epizyme (issuer)
  • PTC Therapeutics (issuer)
  • uniQure (issuer) 
  • Eleven Biotherapeutics (issuer)
  • Concert Pharmaceuticals (issuer)
  • Argos Therapeutics (issuer) 
  • Merrimack Pharmaceuticals (issuer)
  • Verastem (issuer)
  • OvaScience (issuer/Form 10 process)
  • Emergent BioSolutions (issuer)
  • Cynosure (issuer)
  • Icagen (issuer)
  • Eyetech Pharmaceuticals (issuer)
  • Diatide (issuer)
  • Idera Pharmaceuticals (issuer)
  • Ascent Pediatrics (issuer)
  • Thermo Vision (issuer)
  • Renaissance Solutions (issuer)
  • Breakaway Solutions (issuer)
  • Aegerion (Leerink Swann and Lazard)
  • NuPathe Inc. (Leerink Swann and Lazard)
  • Altus Pharmaceuticals (Merrill Lynch and Morgan Stanley)
  • Labopharm (Merrill Lynch and Bank of America)
  • Targacept (Morgan Stanley)
  • GTx (Goldman Sachs)
  • Barrier Therapeutics (Morgan Stanley)
  • Progenics Pharmaceuticals (Oppenheimer & Co.)
  • Virus Research Institute (Oppenheimer & Co.)
  • Also represented PTC Therapeutics, TransMedics, Xanodyne and Voyager Pharmaceuticals and the underwriters for Aldagen, ActivBiotics and Archemix in withdrawn offerings

Follow-on Equity Offerings

  • Ophthotech (issuer)
  • Epizyme (issuer)
  • PTC Therapeutics (issuer)
  • Cynosure (issuer/common stock shelf takedown)
  • Savient Pharmaceuticals (issuer/common stock shelf takedowns)
  • Millennium Pharmaceuticals (issuer/common stock shelf takedown)
  • Transkaryotic Therapies (issuer/common stock shelf takedowns)
  • Idera Pharmaceuticals (issuer/common stock shelf takedown)
  • LTX (issuer/common stock shelf takedown)
  • Saucony (issuer/common stock)
  • Altus Pharmaceuticals (Morgan Stanley)
  • Alexion Pharmaceuticals (Goldman Sachs)
  • Lexicon Genomics (Morgan Stanley)
  • Vicuron Pharmaceuticals (Morgan Stanley)
  • Barrier Therapeutics (Morgan Stanley)
  • Progenics Pharmaceuticals (CIBC/UBS)
  • Genome Therapeutics (CIBC)
  • GTx (Lazard)
  • Fisher Scientific (Goldman Sachs)

Debt Offerings

  • The Medicines Company (issuer/144A convertible note offering with related hedging transactions)
  • Millennium Pharmaceuticals (issuer/144A convertible note offering and WKSI shelf convertible note offering)
  • Thermo Electron (issuer/144A note offering)
  • American Tower (issuer/144A note offering)
  • Savient Pharmaceuticals (issuer/WKSI shelf convertible note offering) 
  • Transkaryotic Therapies (issuer/convertible note shelf takedown)
  • AtheroGenics (issuer/144A convertible note offering)
  • Cubist Pharmaceutics (Goldman Sachs/WKSI shelf convertible note offering)

Mergers and Acquisitions – Life Sciences

  • Millennium Pharmaceuticals in its acquisition by Takeda Pharmaceuticals  
  • ISTA Pharmaceuticals in its acquisition by Bausch & Lomb
  • The Medicines Company in its acquisitions of Targanta Therapeutics Corporation, Incline Therapeutics, Rempex Pharmaceuticals and Curacyte GmbH
  • Millennium Pharmaceuticals in its acquisitions of COR Therapeutics, Leukosite, Chemgenics and IDM Pharma
  • Link Medicine in the sale of its assets to AstraZeneca
  • Nabriva in its merger agreement with Forest Laboratories 
  • PAREXEL International Corporation in its acquisitions of California Clinical Trials and APEX International Clinical Research
  • Transkaryotic Therapies in its acquisition by Shire Pharmaceuticals Group plc
  • Eyetech Pharmaceuticals in its acquisition by OSI Pharmaceuticals
  • Icagen in its acquisition by Pfizer
  • Stromedix in its acquisition by Biogen Idec
  • Rhythmia in its acquisition by Boston Scientific
  • Cardiokine in its acquisition by Cornerstone Therapeutics
  • Levitronix LLC in the sale of its medical products business to Thoratec Corp.
  • Taligen Therapeutics in its acquisition by Alexion Pharmaceuticals
  • Alnara Pharmaceuticals in its acquisition by Eli Lilly
  • GlycoFi in its acquisition by Merck
  • Domantis in its acquisition by GSK
  • Xanthus Pharmaceuticals in its acquisition by Antisoma plc
  • Xanodyne Pharmaceuticals in its product sale of Lysteda to Ferring
  • Savient Pharmaceuticals in its dispositions of its BTG and Rosemont subsidiaries
  • Millennium Pharmaceuticals in its acquisitions of the minority interests in Millennium Predictive Medicine and Millennium BioTherapeutics

Mergers and Acquisitions – Other

  • Many acquisitions and dispositions of public companies, divisions of public companies and private companies for Thermo Fisher Scientific
  • Many acquisitions and dispositions of public companies, divisions of public companies and private companies for PerkinElmer
  • Many acquisitions and dispositions of divisions of public companies and private companies for Williams plc
  • LTX in its merger of equals with Credence Systems
  • Thermo Electron in its acquisitions of minority interests in seven publicly traded subsidiaries
  • Berkshire Realty in its LBO by management, Blackstone and Goldman Sachs
  • Berkshire Mortgage Finance in its acquisition by Deutsche Bank
  • Saucony in its acquisition by Stride Rite
  • American Property Finance in its acquisition by Wachovia from Emigrant Savings Bank

Private Equity

  • Many investments representing investment funds and companies involving a range of debt, equity and convertible instruments. Fund clients include MPM Capital, Clarus Ventures, Frazier Healthcare, New Leaf Venture Partners, Sofinnova Ventures, Flagship Ventures, Novartis BioVentures, Advanced Technology Ventures and Boston Millennia Partners

Corporate Collaborations

  • Merrimack Pharmaceuticals in its collaboration with Sanofi-Aventis
  • Merrimack Pharmaceuticals in its collaboration with PharmaEngine
  • The Medicines Company in its collaboration with Bristol-Myers Squibb for Recothrom
  • The Medicines Company in its license of ApoA I Milano from Pfizer
  • Wellstat Therapeutics in its license agreement with Sanofi-Aventis
  • Seaside Therapeutics in its license with Roche
  • Concert Pharmaceuticals in its collaboration with GSK
  • Ophthotech in its license agreement with PDL and Biogen
  • Alpharma in its collaboration with IDEA
  • The Medicines Company in the reacquisition of European rights to Angiox® from Nycomed
  • Fabre-Kramer Pharmaceuticals in its collaboration with GSK
  • Eyetech Pharmaceuticals in its collaboration with Pfizer
  • Icagen in its collaborations with Pfizer, McNeil (J&J), Abbott and BMS
  • Idera Pharmaceuticals in its collaborations with Novartis and Merck and its cross-license with Isis Pharmaceuticals
  • Diatide in its collaboration with Nycomed
  • Potentia in its collaboration with Alcon
  • b3 bio in its collaboration with Roche
  • Leerink Swann in its database agreement with Health Insight Technologies


Honors & Awards

  • Ranked in Band 1 in the life sciences: corporate/commercial category and Band 4 in corporate/M&A by Chambers Global
  • Ranked in Band 1 in the Massachusetts corporate/M&A and Nationwide Life Sciences categories by Chambers USA. Clients describe him as a "great strategist who certainly knows the law well and is exceptionally bright." 
  • Listed as a "Leading Lawyer" in the areas of life sciences and mergers, acquisitions and buyouts: venture capital and emerging companies in The Legal 500 United States
  • Recognized as a "Life Sciences Star" for outstanding transactional work in LMG Life Sciences
  • Recognized as one of the world's leading life sciences lawyers in Who's Who Legal: The International Who's Who of Life Sciences Lawyers
  • Selected by peers for inclusion in Best Lawyers in America in the areas of biotechnology law and corporate law
  • Ranked in the PLC Cross-Border Life Sciences Handbook as a "leading lawyer"
  • Named to the 2005 BTI Client Service All-Star Team as a result of BTI Consulting Group's annual survey of corporate counsel at Fortune 1000 companies to identify those attorneys who provided the highest quality client service and achieved the greatest client satisfaction
  • Named a "Massachusetts Super Lawyer" in corporate finance in Boston Magazine

Insights & News


  • Education

    • JD, Harvard Law School, 1975

      cum laude
    • BA, University of Wisconsin, 1972

      Class Valedictorian, Phi Beta Kappa
  • Admissions

    • Massachusetts

  • Languages

    • French



Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.